Background Molnupiravir and ritonavir-boosted nirmatrelvir are the two leading oral COVID-
19 antiviral treatments, but their antiviral activities in patients have not been compared …

In the pages of The BMJ a decade ago, in the middle of a different pandemic, it came to light
that governments around the world had spent billions stockpiling antivirals for influenza that …

Humanity has faced three recent outbreaks of novel betacoronaviruses, emphasizing the
need to develop approaches that broadly target coronaviruses. Here, we identify 55 …

Objective To compare the effectiveness of molnupiravir, nirmatrelvir-ritonavir, and
sotrovimab with no treatment in preventing hospital admission or death in higher-risk …

Vaccination guidelines for patients treated for hematological diseases are typically
conservative. Given their high risk for severe COVID-19, it is important to identify those …

Patients with multiple myeloma frequently present with substantial immune impairment and
an increased risk for infections and infection-related mortality. The risk for infection with …

Monoclonal antibodies targeting the SARS‐CoV‐2 spike (S) neutralize infection and are
efficacious for the treatment of COVID‐19. However, SARS‐CoV‐2 variants, notably …

Multiple monoclonal antibodies have been shown to be effective for both prophylaxis and
therapy for SARS-CoV-2 infection. Here we aggregate data from randomized controlled …

Somatic hypermutation (SHM) drives affinity maturation and continues over months in SARS-
CoV-2-neutralizing antibodies (nAbs). However, several potent SARS-CoV-2 antibodies …

SARS-CoV-2 infections manifest with a broad spectrum of presentations, ranging from
asymptomatic infections to severe pneumonia and fatal outcomes. This review centers on …